The surgical management of cervical cancer is a highly individualized process. The choice of procedure is dictated by a complex interplay of the tumor's FIGO stage, the specific histology, and the patient's personal goals, such as the desire for fertility preservation. While early-stage disease may allow for conservative approaches, more advanced presentations require radical resections or, in many cases, a shift from surgical to chemoradiation-based treatment strategies.
FIGO Staging and Treatment Selection
Staging is the cornerstone of cervical cancer management. The 2018 FIGO staging system guides clinicians in determining whether a patient is a candidate for surgery or if they require definitive chemoradiation.
For patients with early-stage disease (typically Stage IA through IB1/IB2), surgery is often the primary modality. However, as the disease progresses to Stage IIB or higher, the standard of care shifts toward definitive chemoradiation. This shift is necessary because advanced stages often involve parametrial involvement or regional spread that surgical resection alone cannot reliably clear.
Exam Tip: If a question presents a patient with Stage IIB cervical cancer, the most appropriate next step is typically chemoradiation, not radical hysterectomy.
Hysterectomy Classifications: The Querleu and Morrow System
When surgery is indicated, the extent of the resection is classified using the Querleu and Morrow classification system. This system describes the degree of resection and the level of nerve preservation across three-dimensional planes.
Simple Hysterectomy (Type A)
Type A hysterectomy is indicated for low-risk, early-stage patients (Stage IA1–IB1) who meet specific conservative surgery criteria. These criteria typically include:
- No lymphovascular space invasion (LVSI).
- Tumor size 2 cm.
- Depth of invasion < 10 mm.
Keep reading for free.
Create an account to finish this reading and make it part of your study routine.
Continue reading freeAlready have an account? Log in
Updated

